ABT 560

Drug Profile

ABT 560

Alternative Names: ABT-560; ABT-PR2

Latest Information Update: 05 Feb 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeuroSearch
  • Developer Abbott Laboratories
  • Class
  • Mechanism of Action Alpha4beta2 nicotinic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cognition disorders

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to a new company called AbbVie
  • 21 Oct 2011 ABT 560 is still in Phase-I trials for Cognition disorders in USA
  • 28 Sep 2011 ABT 560 is available for licensing as of 28 Sep 2011. http://neurosearch.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top